Cattran 1977.

Methods	Study design: cross‐over RCT Study duration: NS Study follow‐up: 6 months
Participants	Country: Canada Setting: single centre Male patients; chronic HD for at least 6 months Number randomised/completed (remnant kidney/anephric): 37/29; treatment group (15/3); control group (9/2) Age range: 25 to 66 years Sex (M/F): 37/0 Exclusion criteria: NS
Interventions	Treatment group Nandrolone decanoate: 200 mg IM weekly Duration: 6 months Control group No therapy Co‐interventions Aluminium hydroxide for phosphate control Daily oral supplement containing 150 mg of elemental iron 2.5 mg of folic acid
Outcomes	Hb HCT
Notes	ALT, AST, BUN, SCr, cholesterol, TG, HDL, LDL, mortality, BUN, SCr, total protein, albumin, pre‐albumin, and transferrin were not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Mentioned randomisation, but not detailed
Allocation concealment (selection bias)	Low risk	Allocation concealment mentioned
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	High risk	8 participants withdrew after enrolment
Selective reporting (reporting bias)	Unclear risk	Insufficient reporting to enable assessment
Other bias	High risk	Signed informed consent obtained from all subjects. Participant demographic data not reported. No indication that ethics approval was sought or granted